main-content

27-06-2022 | Prostate cancer | Adis Journal Club | Article

PharmacoEconomics

# Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia

print
PRINT
insite
SEARCH

Authors: Rachel Song, Varinder Jeet, Rajan Sharma, Martin Hoyle & Bonny Parkinson

## Abstract

### Background and Objectives

Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) combined with computed tomography (CT) is a new imaging modality to detect the extra-prostatic spread of prostate cancer. PSMA PET/CT has a higher sensitivity and specificity than conventional imaging (CT ± whole body bone scan [WBBS]). This study conducted a cost-utility analysis of PSMA PET/CT compared with conventional imaging for patients with newly diagnosed, intermediate-risk or high-risk primary prostate cancer.

### Perspective

Australian healthcare perspective.

Tertiary.

### Conclusions

PSMA PET/CT is likely to be more costly than CT+WBBS or CT alone in Australia; however, it is still likely to be considered cost effective compared with conventional imaging.

## View the full open access article

### Key Points for Decision Makers

Prostate-specific membrane antigen positron emission tomography combined with computed tomography is a new and more accurate method to detect prostate cancer.

Previous studies estimated that prostate-specific membrane antigen positron emission tomography/computed tomography is likely to be cost saving compared with conventional imaging.

We found that prostate-specific membrane antigen positron emission tomography/computed tomography is likely to be more costly than computed tomography plus a whole-body bone scan or computed tomography alone in Australia; however, it is still likely to be considered cost effective for patients with newly diagnosed, intermediate-risk or high-risk primary prostate cancer.

print
PRINT